Radiatric Inc.


Radiatric Inc. is dedicated to developing and commercializing innovative technologies to improve outcomes for patients with bacteremia, moderate to severe sepsis, and septic shock. Their flagship product, the RAD-01 system, is a non-antibiotic investigational device designed to treat bloodborne infections by lowering pathogenic CFUs in extracorporeal blood. The company focuses on non-pharmacological methods to deactivate pathogens, aiming to reduce the mortality and long-term effects associated with sepsis.

Industries

N/A

Nr. of Employees

small (1-50)


Patents

Extracorporeal blood disinfection systems and methods

US-12544499-B2

View Details

Products

Extracorporeal light-based blood treatment system

Investigational extracorporeal device that circulates patient blood through a light exposure module using visible and near-UV wavelengths to inactivate bacteria in blood without exogenous photosensitizers; designed for use as an adjunct to dialysis or hemoperfusion and with antibiotics.


Services

Engagements to discuss partnership, licensing, and collaboration opportunities related to development, testing, and commercialization of the extracorporeal light-based antimicrobial device.

Expertise Areas

  • Extracorporeal blood treatment
  • Photodynamic antimicrobial therapy
  • Sepsis and bacteremia device development
  • Clinical device integration with dialysis/CRRT/hemoperfusion
  • Show More (2)

Key Technologies

  • Visible and near-UV light disinfection
  • Photodynamic inactivation via endogenous porphyrin activation
  • Extracorporeal blood circulation modules
  • Reactive oxygen species-mediated microbial killing
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.